Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085591 · Präparat HOS-083163
An additive effect on QT interval prolongation between Fareston and the following drugs and other
medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an
increased risk of ventricular arrhythmias, including Torsade de pointes. Therefore co-administration
of Fareston with any of the following medicinal products is contraindicated (see also section 4.3):
- antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide)
- antiarrhythmics class III (e.g. amiodarone, sotalol, dofetilide, ibutilide)
- neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride)
- certain antimicrobials agents (moxifloxacin, erythromycin IV, pentamidine, antimalarials
particularly halofantrine)
- certain antihistaminics (terfenadine, astemizole, mizolastine)
- others (cisapride, vincamine IV, bepridil, diphemanil).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) sotalol (HOS-085597) cisapride (HOS-085610) bepridil (HOS-085612) dofetilide (HOS-085598) halofantrine (HOS-085606) ibutilide (HOS-085599) quinidine (HOS-085593) hydroquinidine (HOS-085594) sultopride (HOS-085603) lead (HOS-085592) disopyramide (HOS-085595) diphemanil (HOS-085613) pimozide (HOS-085600) erythromycin (HOS-084514) moxifloxacin (HOS-085604) astemizole (HOS-085608) pentamidine (HOS-085605) haloperidol (HOS-085602) amiodarone (HOS-085596) terfenadine (HOS-085607) vincamine (HOS-085611) mizolastine (HOS-085609)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage 9429395d1b572fb000ebac0968a84f8f195781287110169960c945b4772df6c6 · Zeichen 0–900 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35–36
HOS-086388 · Präparat HOS-083284
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) methylergonovine (HOS-086155) propafenone (HOS-084530) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) flecainide (HOS-086203) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f76b82bf2af9e33f5778d35af3ff4a8ea2ea8d392666af7950204db67ec4ac88 · Zeichen 1234–5743 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 18
HOS-086278 · Präparat HOS-083284
Antipsychotics/Neuroleptics
Clozapine, pimozide Ritonavir co-administration is likely to result in increased plasma concentrations of
clozapine or pimozide and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9b673d4bcfd59f47bb6c54c40be4618c80a44972f74bc511b794d09c8b64bb1 · Zeichen 37523–37792 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086458 · Präparat HOS-083284
Antipsychotics/Neuroleptics
Clozapine, pimozide Ritonavir co-administration is likely to result in increased plasma concentrations of
clozapine or pimozide and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pimozide (HOS-085600) clozapine (HOS-086149)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9b673d4bcfd59f47bb6c54c40be4618c80a44972f74bc511b794d09c8b64bb1 · Zeichen 39314–39583 im Abschnitt
Wechselwirkungen · Exelon
Exelon 1.5 mg hard capsules Exelon 3.0 mg hard capsules Exelon 4.5 mg hard capsules Exelon 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-087795 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1110–1692 im Abschnitt
Wechselwirkungen · Exelon
Exelon 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 22
HOS-087828 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1111–1693 im Abschnitt
Wechselwirkungen · Exelon
Exelon 4.6 mg/24 h transdermal patch Exelon 9.5 mg/24 h transdermal patch Exelon 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 39
HOS-087855 · Präparat HOS-083555
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T11:34:00Z · SHA-256 de7d3796de42471f695291c0766fcf1a2fe650dc43b810dbff52cb58532f22d3 · Passage ff4a6089869c9cad9b1692c6af2335103d7143b0e75d26f251dc054a8dc03d56 · Zeichen 1197–1695 im Abschnitt
Wechselwirkungen · Prometax
Prometax 1.5 mg hard capsules Prometax 3.0 mg hard capsules Prometax 4.5 mg hard capsules Prometax 6.0 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-090120 · Präparat HOS-084005
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1110–1692 im Abschnitt
Wechselwirkungen · Prometax
Prometax 2 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 20
HOS-090145 · Präparat HOS-084005
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
diphemanil, erythromycin IV, halofantrin, mizolastin, methadone, pentamidine and moxifloxacine
should be observed with caution and clinical monitoring (ECG) may also be required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) methadone (HOS-086198) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) diphemanil (HOS-085613) amisulpride (HOS-087798) pimozide (HOS-085600) erythromycin (HOS-084514) pentamidine (HOS-085605) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 154d6b61b7e191c68cf01d41c614dc042e430118597578b05335dd0fcb9503bd · Zeichen 1111–1693 im Abschnitt
Wechselwirkungen · Prometax
Prometax 4.6 mg/24 h transdermal patch Prometax 9.5 mg/24 h transdermal patch Prometax 13.3 mg/24 h transdermal patch · Abschnitt 4.5 · PDF-Seite 35
HOS-090170 · Präparat HOS-084005
Since bradycardia constitutes a risk factor in the occurrence of torsades de pointes, the combination of
rivastigmine with QT prolongation- or torsades de pointes-inducing medicinal products such as
antipsychotics i.e. some phenothiazines (chlorpromazine, levomepromazine), benzamides (sulpiride,
sultopride, amisulpride, tiapride, veralipride), pimozide, haloperidol, droperidol, cisapride, citalopram,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): citalopram (HOS-087802) sulpiride (HOS-087797) cisapride (HOS-085610) veralipride (HOS-087800) droperidol (HOS-087801) chlorpromazine (HOS-087796) sultopride (HOS-085603) amisulpride (HOS-087798) pimozide (HOS-085600) haloperidol (HOS-085602) tiapride (HOS-087799)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 40e0d9446db8c9b0543775c3feb5f361ddfae62f03137c84a0fd80d22e575530 · Zeichen 1199–1602 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42–43
HOS-108988 · Präparat HOS-093083
42
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from
this agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma.
The concomitant administration with
quetiapine is contraindicated (see
section 4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of
ergotamine, methylergonovine ergot derivatives leading to acute ergot
toxicity, including vasospasm and
ischaemia (see section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk
of serious arrhythmias from this agent
(see section 4.5).
Hepatitis C virus Elbasvir/grazoprevir Increased risk of alanine transaminase
direct acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) methylergonovine (HOS-086155) cisapride (HOS-085610) hepatitis C virus (HOS-108813) ergot alkaloids (HOS-108807) lead (HOS-085592) grazoprevir (HOS-108815) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) dihydroergotamine (HOS-086152) alanine (HOS-088949)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 513868d9cbc220f8b16283ba405e7ae3a7eba9be191b93bb320faa5cdf17028c · Zeichen 3976–6635 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77–78
HOS-109062 · Präparat HOS-093083
77
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and during
the ramp-up phase (see section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious arrhythmias
from these agents (see section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or
other serious adverse effects from this
agent (see section 4.5).
Quetiapine Increased plasma concentrations of
quetiapine which may lead to coma. The
concomitant administration with
quetiapine is contraindicated (see section
4.5).
Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot
ergotamine, methylergonovine derivatives leading to acute ergot toxicity,
including vasospasm and ischaemia (see
section 4.5).
GI motility agent Cisapride Increased plasma concentrations of
cisapride. Thereby, increasing the risk of
serious arrhythmias from this agent (see
section 4.5).
Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase
acting antivirals (ALT) elevations (see section 4.5).
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) methylergonovine (HOS-086155) cisapride (HOS-085610) hepatitis C virus (HOS-108813) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) lead (HOS-085592) grazoprevir (HOS-108815) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) dihydroergotamine (HOS-086152) alanine (HOS-088949)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage deedafd686f2a7856b9535fd14424479a75da74b88007e447ddb2a759abcc3fe · Zeichen 2941–6504 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 19–20
HOS-108904 · Präparat HOS-093083
19
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose
adjustment of Kaletra
400 mg/400 mg (i.e. Kaletra
400/100 mg + ritonavir 300 mg)
twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders.
Therefore, this co-administration
should be avoided unless judged
strictly necessary. If this
co-administration is judged
unavoidable, increased dose of
Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has
been initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration
lopinavir/ritonavir, with lurasidone is contraindicated
concentrations of lurasidone are (see section 4.3).
expected to increase.
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, Kaletra and pimozide is
concentrations of pimozide are contraindicated as it may increase
expected to increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, Kaletra and quetiapine is
concentrations of quetiapine are contraindicated as it may increase
expected to increase. quetiapine-related toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) pimozide (HOS-085600) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0cd97f605d9ff9f95bd037eca67e54d94e990128412fa438a0aa4c28977553c1 · Zeichen 38367–41870 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55–56
HOS-109015 · Präparat HOS-093083
55
Rifampicin Lopinavir: Co-administration of Kaletra with
Large decreases in lopinavir rifampicin is not recommended as
concentrations may be observed the decrease in lopinavir
due to CYP3A induction by concentrations may in turn
rifampicin. significantly decrease the lopinavir
therapeutic effect. A dose adjustment
of Kaletra 400 mg/400 mg (i.e.
Kaletra 400/100 mg + ritonavir
300 mg) twice daily has allowed
compensating for the CYP 3A4
inducer effect of rifampicin.
However, such a dose adjustment
might be associated with ALT/AST
elevations and with increase in
gastrointestinal disorders. Therefore,
this co-administration should be
avoided unless judged strictly
necessary. If this co-administration is
judged unavoidable, increased dose
of Kaletra at 400 mg/400 mg twice
daily may be administered with
rifampicin under close safety and
therapeutic drug monitoring. The
Kaletra dose should be titrated
upward only after rifampicin has been
initiated (see section 4.4).
Antipsychotics
Lurasidone Due to CYP3A inhibition by The concomitant administration with
lopinavir/ritonavir, concentrations lurasidone is contraindicated (see
of lurasidone are expected to section 4.3).
increase.
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase the
increase. risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) pimozide (HOS-085600) lurasidone (HOS-086148)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c8939a16b64f6d8ec4a19ded0cb5af8a6d3c243259de96cb30a89f8088ddcbc4 · Zeichen 37143–40650 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91–92
HOS-109092 · Präparat HOS-093083
91
Pimozide Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and pimozide is
of pimozide are expected to contraindicated as it may increase
increase. the risk of serious haematologic
abnormalities or other serious
adverse effects from this agent (see
section 4.3)
Quetiapine Due to CYP3A inhibition by Concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and quetiapine is
of quetiapine are expected to contraindicated as it may increase
increase. quetiapine-related toxicity.
Benzodiazepines
Midazolam Oral Midazolam: Kaletra must not be co-administered
AUC: ↑ 13-fold with oral midazolam (see section
Parenteral Midazolam: 4.3), whereas caution should be
AUC: ↑ 4-fold used with co-administration of
Due to CYP3A inhibition by Kaletra and parenteral midazolam.
lopinavir/ritonavir If Kaletra is co-administered with
parenteral midazolam, it should be
done in an intensive care unit (ICU)
or similar setting which ensures
close clinical monitoring and
appropriate medical management in
case of respiratory depression
and/or prolonged sedation. Dosage
adjustment for midazolam should be
considered especially if more than a
single dose of midazolam is
administered.
Beta2-adrenoceptor agonist (long acting)
Salmeterol Salmeterol: The combination may result in
Concentrations are expected to increased risk of cardiovascular
increase due to CYP3A inhibition adverse events associated with
by lopinavir/ritonavir. salmeterol, including QT
prolongation, palpitations and sinus
tachycardia.
Therefore, concomitant
administration of Kaletra with
salmeterol is not recommended (see
section 4.4).
Calcium channel blockers
Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic
and Nicardipine Nicardipine: and adverse effects is recommended
Concentrations may be increased when these medicines are
due to CYP3A inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Corticosteroids
Dexamethasone Lopinavir: Clinical monitoring of antiviral
Concentrations may be decreased efficacy is recommended when
due to CYP3A induction by these medicines are concomitantly
dexamethasone. administered with Kaletra.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) pimozide (HOS-085600) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 703aea6daa39d7a84dcc105bf1c63b26907c5686341c713d7b68e5df123b8727 · Zeichen 40354–44819 im Abschnitt
Gegenanzeigen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5
HOS-109425 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) quinidine (HOS-085593) ergot alkaloids (HOS-108807) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92d039d4c373d2ccbb0905dc4377f6a8efd63303319839f8da1593b24c1c81cc · Zeichen 515–724 im Abschnitt
Gegenanzeigen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.3 · PDF-Seite 36
HOS-109524 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
• Venetoclax: Coadministration contraindicated at initiation and during venetoclax dose titration
phase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 392392b9fe6da7258d9d0da5625b43e73df89387373d420d8ae08c8a730299d2 · Zeichen 515–979 im Abschnitt
Gegenanzeigen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.3 · PDF-Seite 69
HOS-109587 · Präparat HOS-093201
• Terfenadine
• Astemizole
• Cisapride
• Pimozide
• Lurasidone
• Quinidine
• Ivabradine
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine)
• Sirolimus
• Naloxegol
• Tolvaptan
• Finerenone
• Eplerenone
• Voclosporin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) eplerenone (HOS-089050) quinidine (HOS-085593) finerenone (HOS-109430) tolvaptan (HOS-109429) ergot alkaloids (HOS-108807) naloxegol (HOS-109428) ivabradine (HOS-109426) pimozide (HOS-085600) astemizole (HOS-085608) sirolimus (HOS-085172) voclosporin (HOS-109432) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 52e206f10d0171fc7c859121398e23adfe815eb2cdb7b4fd04fb205bc3c3bde3 · Zeichen 515–854 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.